A084650 Stock Overview
Engages in the research and development of biotechnology products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
LabGenomics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,190.00 |
| 52 Week High | ₩6,500.00 |
| 52 Week Low | ₩2,085.00 |
| Beta | -1.04 |
| 11 Month Change | -11.16% |
| 3 Month Change | -27.84% |
| 1 Year Change | -38.74% |
| 33 Year Change | -47.23% |
| 5 Year Change | 114.01% |
| Change since IPO | 84.42% |
Recent News & Updates
Shareholder Returns
| A084650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.9% | -1.1% | 0.2% |
| 1Y | -38.7% | 17.7% | 7.1% |
Return vs Industry: A084650 underperformed the KR Biotechs industry which returned 18.6% over the past year.
Return vs Market: A084650 underperformed the KR Market which returned 7.4% over the past year.
Price Volatility
| A084650 volatility | |
|---|---|
| A084650 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A084650's share price has been volatile over the past 3 months.
Volatility Over Time: A084650's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 183 | Sung Chin | www.labgenomics.co.kr |
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
LabGenomics Co., Ltd. Fundamentals Summary
| A084650 fundamental statistics | |
|---|---|
| Market cap | ₩162.59b |
| Earnings (TTM) | -₩18.04b |
| Revenue (TTM) | ₩78.36b |
2.1x
P/S Ratio-9.0x
P/E RatioIs A084650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A084650 income statement (TTM) | |
|---|---|
| Revenue | ₩78.36b |
| Cost of Revenue | ₩48.49b |
| Gross Profit | ₩29.87b |
| Other Expenses | ₩47.91b |
| Earnings | -₩18.04b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -242.97 |
| Gross Margin | 38.12% |
| Net Profit Margin | -23.02% |
| Debt/Equity Ratio | 20.7% |
How did A084650 perform over the long term?
See historical performance and comparison